Drug Resistance Updates

Papers
(The H4-Index of Drug Resistance Updates is 52. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Editorial Board590
Editorial Board303
Molecular subtype changes after acquiring resistance to tarlatamab in small cell lung cancer257
Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor238
PARP inhibition elicits NK cell-associated immune evasion via potentiating HLA-G expression in tumor221
N6-methyladenosine modification of 3'tRF-AlaAGC impairs PD-1 blockade efficacy by promoting lactic acid accumulation in the tumor microenvironment of gastric carcinoma216
Plasmid-borne tigecycline resistance gene tet(X4) in Salmonella enterica and Escherichia coli isolates from a pediatric patient with diarrhea215
Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma204
Sciatic nerve stimulation enhances NK cell cytotoxicity through dopamine signaling and synergizes immunotherapy in triple-negative breast cancer179
Unraveling the secrets: Evolution of resistance mediated by membrane proteins150
Profiling the landscape of carbapenem resistance and hypervirulence in Klebsiella pneumoniae: A global epidemiological analysis of the plasmidome147
Erratum to “A highly potent small-molecule antagonist of exportin-1 selectively eliminates CD44+ CD24- enriched breast cancer stem-like cells” [Drug Resist. Updates 66 (2023) 100903]146
Oridonin derivative DLC13 targeting proliferating cell nuclear antigen to overcome oxaliplatin resistance in colorectal cancer144
Exosomal circular RNAs: A chief culprit in cancer chemotherapy resistance143
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects139
Editorial Board135
Evolution of RND efflux pumps in the development of a successful pathogen133
A novel frameshift mutation in a case of therapy-resistant metastatic pheochromocytoma129
Replacing the tropolonic methoxyl group of colchicine with methylamino increases tubulin binding affinity with improved therapeutic index and overcomes paclitaxel cross-resistance129
Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer117
Point mutation P174L of the penA gene endowing ceftazidime resistance to Burkholderia pseudomallei in China114
Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges100
Collateral sensitivity between tetracyclines and aminoglycosides constrains resistance evolution in carbapenem-resistant Klebsiella pneumoniae99
Novel insights into taxane pharmacology: An update on drug resistance mechanisms, immunomodulation and drug delivery strategies94
Targeting DNA damage response pathways in tumor drug resistance: Mechanisms, clinical implications, and future directions90
A novel platinum(IV) prodrug, gramine-Pt(IV) enhances chemoimmunotherapy by activating cGAS-STING and modulating TGF-β-MHC-I axis89
Peptide nanonet trapping suppresses bacterial motility and delays antibiotic resistance emergence88
Enzymatic bionanocatalysts for combating peri-implant biofilm infections by specific heat-amplified chemodynamic therapy and innate immunomodulation85
IFNα2b modulates anti-tumor immune responses involving STAT3-associated dendritic cell dysfunction in JAK2v617f-positive myeloproliferative neoplasms80
Corrigendum to “RNF26 regulating tumor immunogenicity of hepatocellular carcinoma by degrading GRP78 and instigating ER stress” [Drug Resist. Updat. 86 (2026) 101375]78
The novel strategy to overcome the drug-resistant lung cancer: Dual targeting delivery of PROTAC to inhibit cancer-associated fibroblasts and lung cancer cells77
Inhibition of SIRT7 overcomes sorafenib acquired resistance by suppressing ERK1/2 phosphorylation via the DDX3X-mediated NLRP3 inflammasome in hepatocellular carcinoma75
TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770–5p axis in PDAC74
Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs73
Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs70
The role of ABCC10/MRP7 in anti-cancer drug resistance and beyond68
Targeting anoikis resistance as a strategy for cancer therapy67
Editorial Board67
Heterogeneity of SOS response expression in clinical isolates of Escherichia coli influences adaptation to antimicrobial stress65
Research progress on gene mutations and drug resistance in leukemia63
Global population structure and genomic surveillance framework of carbapenem-resistant Salmonella enterica63
Novel mobile colistin resistance gene mcr-4.9 in Vibrio cholerae from migratory birds63
PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity62
Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers61
Emergence of silent NDM-1 carbapenemase gene in carbapenem-susceptible Klebsiella pneumoniae: Clinical implications and epidemiological insights59
Molecular profiling of chemotherapy-resistant breast cancer reveals DNA methylation remodeling associated with the acquisition of paclitaxel resistance58
The role of tumor microenvironment and signaling pathways in regulating breast cancer stem cells: Implications for therapy resistance and tumor recurrence56
Single-cell transcriptome analysis of patient-derived organoids captures inter- and intratumor heterogeneity and uncovers targetable pathways in high grade serous ovarian cancer56
Overcoming cancer chemotherapy resistance by the induction of ferroptosis54
Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma54
Myeloid immune checkpoint blockade overcomes antibiotic resistance in bone infection by enhancing efferocytosis and suppressing MSC PANoptosis52
Current therapy and drug resistance in metastatic castration-resistant prostate cancer52
0.063138008117676